Pursuant to Regulation 30 read with Para A of Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time, Aarti Pharmalabs has informed that it enclosed schedule for the Analyst / Institutional Investor Meetings. Additionally, no unpublished price sensitive information relating to the Company will be disclosed during these interactions with Analysts/Institutional Investors.
The above information is a part of company’s filings submitted to BSE.
